While the field has struggled with previous TNFα targeting therapies in MS [48, 65, 66], a very cogent argument can be made (and indeed has been made [67]) that our deeper understanding of the complexities inherent to TNFα signaling calls for renewed efforts to therapeutically target soluble TNFα in patients with MS. This evidence concerns the gene TNF and myeloid sarcoma.